Rhythm Pharmaceuticals, Inc. Common Stock

RYTMNASDAQ • USD
115.02 USD
↗ 5.16 (4.70%)AT CLOSE (03:59 PM EST)
114.40
↘ 0.62 (0.54%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
114.40
↘ 0.62 (0.54%)
🔴Market: CLOSED

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) is currently trading at $115.02. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Nov 13, 2026.

Open?$109.81
High?$117.84
Low?$107.86
Prev. Close?$109.86
Volume?1.2M
Avg. Volume?1.5M
VWAP?$113.16
Rel. Volume?0.79x
Bid / Ask
Bid?$111.73 × 100
Ask?$116.50 × 500
Spread?$4.77
Midpoint?$114.12
Valuation & Ratios
Market Cap?8.0B
Shares Out?69.3M
Float?64.4M
Float %?94.0%
P/E Ratio?N/A
P/B Ratio?39.57
EPS?-$2.86
Dividend?0.02%
Ex-Dividend?N/A
News
Profile
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Employees
414
Market Cap
8.0B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2017-10-05
Address
222 BERKELEY STREET
BOSTON, MA 02116
Phone: 857-264-4280
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
100
Momentum?
83
Short Sent.?
34
Piotroski F-Score?3/9Weak
Altman Z-Score?15.04Safe
Confidence?57%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?18.13%High
Short Interest?11.7M
Days to Cover?23.3
Free Float64.4M
Avg Daily Volume500.5K
Settlement Date2026-10-30
Financial Health
Current Ratio?2.78Strong
Quick Ratio?2.57Strong
Cash Ratio?0.26Low
Debt/Equity?0.51Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
39.57HIGH▾
P/S?
Peers
100
S&P
3
28.40HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-43.2CHEAP▾
EV/Sales?
Peers
100
S&P
3
28.63HIGH▾
Returns & Efficiency
ROE?
S&P
3
-98.4%WEAK▾
ROA?
S&P
3
-44.8%WEAK▾
Cash Flow & Enterprise
FCF?$-83241000
Enterprise Value?$8.0B
Fundamentals ratios updated end of day